Samuel R, Knight SR, Adams R, Das P, Dorth J, Finch D, Guren MG, Hawkins MA, Moug S, Rajdev L, Sebag-Montefiore D, Renehan AG, Fish R, plus the CORMAC-2 collaborators(2024) International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set EClinicalMedicine, 78, 102939 DOI 10.1016/j.eclinm.2024.102939, PubMed 39720423
Mala T, Abelseth BK, Al-Haidari G, Dørum LMR, Hatlevoll I, Rekstad LC, Stenvold H, Øvrebø KK, Aahlin EK(2024) [Not Available] Tidsskr Nor Laegeforen, 144(15) DOI 10.4045/tidsskr.24.0547, PubMed 39692659
Lordick F, Mauer ME, Stocker G, Cella CA, Ben-Aharon I, Piessen G, Wyrwicz L, Al-Haidari G, Fleitas-Kanonnikoff T, Boige V, Lordick Obermannová R, Martens UM, Gomez-Martin C, Thuss-Patience P, Arrazubi V, Avallone A, Shiu KK, Artru P, Brenner B, Buges Sanchez C, Chau I, Lorenzen S, Daum S, Sinn M, Merelli Bet al.(2024) Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study Ann Oncol(in press) DOI 10.1016/j.annonc.2024.10.829, PubMed 39542422